KRAS and colorectal carcinoma: Recently, results from the CodeBreak300 trial have been published, comparing the combination of sotorasib and panitumumab versus (vs.)standard-of-care in chemorefractory metastatic KRAS G12C-mutated CRC, showing an improvement in the median PFS (5.6 months vs. 2.2 months) and in ORR (26.4% vs. 0%) [25].